This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by LaCasce, A. S. Search for Related Content PubMed PubMed Citation Articles by LaCasce, A. S.

Lymphoma Series: Variants of Large-Cell Lymphoma

Post-Transplant Lymphoproliferative Disorders

Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Key Words. PTLD • Early Lesion • Polymorphic PTLD • Monomorphic PTLD

Correspondence: Ann S. LaCasce, M.D., Dana-Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115, USA. Telephone: 617-632-5959 Fax: 617-632-5890; e-mail: Ann_LaCasce{at}dcfi.harvard.edu

Post-transplant lymphoproliferative disorder is the most common malignancy, with the exception of skin cancer, after solid organ transplantation in adults. The incidence varies according to the transplanted organ and is often associated with Epstein-Barr virus. Prognosis is variable, due in part to the heterogeneity of the disease, which ranges from reactive plasmacytic hyperplasia to aggressive monoclonal disease.

This article has been cited by other articles:

				J. Pascual Post-transplant lymphoproliferative disorder--the potential of proliferation signal inhibitors Nephrol. Dial. Transplant., May 1, 2007; 22(suppl_1): i27 - i35. [Abstract] [Full Text] [PDF]